Blood Clots and Behçet's Disease Study
Treatments studied
Part of Blood & lymphatic, Eyes & vision, Genetic & congenital, Heart & circulation, Mouth & dental, Skin clinical trials.
This study looks at how Behçet's disease affects blood clotting. If you have Behçet's disease and are between 18–70, you may help doctors understand why some people with Behçet's develop dangerous blood clots.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a diagnosis of Behçet's disease (based on the international criteria).
- You must be willing to sign a consent form agreeing to take part.
- You cannot have another inflammatory skin disease (like psoriasis or eczema).
- You cannot be pregnant or breastfeeding.
- You cannot be taking medications that make blood clots more likely (like some hormone therapies).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at the health records and blood tests of children and young adults with Behçet disease to learn more about the condition. It also compares their results with healthy children to find clues that may help doctors better understand and treat Behçet disease.
This study looks at how the thickness of the femoral vein wall and certain markers of inflammation relate to Behcet disease. It may help doctors better understand and monitor the condition.
This trial tests whether adding a blood thinner (anticoagulant) to steroid therapy is more effective than steroids alone for treating deep vein thrombosis (a blood clot in a large vein) in people with Behçet's syndrome. It aims to find the best way to prevent future clots and reduce side effects.
This Phase 2 trial tests tocilizumab and tofacitinib to see if they can better control vascular (blood-vessel) Behçet’s syndrome. It may help by lowering inflammation and reducing complications from aneurysms in the aorta or peripheral arteries.
This trial is for people who have already completed a prior study of the drug HSK44459 for Behçet's disease. It will continue to monitor the safety and effects of the drug over a longer period.
This trial compares standard immunosuppressive therapy alone versus adding a blood thinner (rivaroxaban) for treating newly diagnosed blood clots in the legs of people with Behcet's disease. It aims to see if adding the anticoagulant improves clot resolution without increasing bleeding risk.
Hear when a new Behçet Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.